Chinese Infrastructure Projects Appear on Global Currency in New Book Celebrating Belt and Road Imprint
BEIJING, May 23, 2025 /PRNewswire/ -- A news report from Xinhuanet:
A new publication highlighting the appearance of Chinese-built infrastructure on foreign currency was unveiled at a book launch and symposium in Beijing on May 19, underscoring China's global reach through its Belt and Road Initiative.
The book, Chinese Imprints on World Currency, chronicles how infrastructure projects linked to China have been featured on coins and banknotes issued by countries around the world, casting these structures as enduring symbols of the country's international partnerships under the Belt and Road framework.
The event drew a cross-section of government officials and corporate leaders, including Hong Lei, Assistant Minister of Foreign Affairs; Wang Haihuai, General Manager of China Communications Construction Company (CCCC); Du Xiaojian, author of the book; and senior executives from state-owned companies. Ambassadors from over 10 countries, including Cape Verde, Algeria, Fiji, Sri Lanka, and Egypt, were also in attendance.
The book documents 121 coins and banknotes issued by 58 countries, each telling a unique story of China's global partnerships through infrastructure. These numismatic records vividly illustrate the BRI's role in strengthening international ties.
Among the featured works are 18 projects constructed by CCCC — the highest number credited to any single company in the collection — including Sri Lanka's Hambantota Port, Croatia's Pelješac Bridge, and Guinea's Kaleta Hydropower Station.
In prepared remarks, Mr. Hong Lei called the publication a timely contribution, noting that it reflects what he described as "the inevitable trend toward a shared future for humanity". He reiterated China's commitment to global cooperation in realizing this vision.
Mr. Wang Haihuai shared insights from CCCC's participation in the Belt and Road Initiative. He reaffirmed the company's dedication to upholding the spirit of the Silk Road while contributing to global sustainable development and the shared future of mankind.
Diplomats in attendance praised the Belt and Road Initiative's accomplishments, voicing interest in strengthening cultural and economic ties with Beijing.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
Seoul shares nearly flat amid renewed tariff woes
South Korean stocks finished slightly higher Monday, as investors took a wait-and-see posture ahead of the crucial presidential election amid signs of renewed trade tensions between the United States and China. The local currency rose against the US dollar. The benchmark Korea Composite Stock Price Index added 1.3 points, or 0.05 percent, to close at 2,698.97. Trade volume was moderate at 320.32 million shares worth 7.99 trillion won ($5.82 billion), with losers beating winners 523 to 369. Foreign and retail investors bought a net 127.34 billion won and 98.7 billion won worth of stocks, respectively, while institutions sold 240.17 billion won worth of shares. The index opened lower but soon turned higher, rising nearly 1 percent. But it had moved in and out of negative territory before ending slightly higher. Investor sentiment was dampened as US President Donald Trump said last week that he planned to double tariffs on foreign imports of steel to 50 percent. He also upped trade tensions by accusing China of violating a trade agreement with the US ahead of a scheduled call with Chinese President Xi Jinping to address trade issues. On the domestic front, South Korean voters were set to cast their ballots to choose a president Tuesday after former President Yoon Suk Yeol was ousted following the short-lived imposition of martial law. Front-runner Lee Jae-myung of the Democratic Party was vying against Kim Moon-soo of the conservative People Power Party. Top-cap shares finished mixed. Market bellwether Samsung Electronics surged 1.07 percent to 56,800 won, and its rival SK hynix jumped 1.47 percent to 207,500 won. But major battery maker LG Energy Solution fell 0.52 percent to 284,500 won, and leading biotech firm Samsung Biologics edged down 0.1 percent to 1.03 million won. Steelmakers lost ground. No. 1 steelmaker POSCO Holdings sank 2.4 percent to 244,000 won, and Hyundai Steel tumbled 2.66 percent to 27,450 won. Carmakers also fell. Top carmaker Hyundai Motor dipped 0.7 percent to 184,000 won, and its sister Kia Motors went down 1.12 percent to 88,400 won. Defense giant Hanwha Aerospace advanced 2.96 percent to 835,000 won, while leading financial firm KB Financial retreated 4.12 percent to 100,000 won. The local currency was quoted at 1,373.1 won against the greenback at 3:30 p.m., up 7 won from the previous session. (Yonhap)
Korea Herald
2 hours ago
- Korea Herald
J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
Significant anti-tumor responses and reduction of brain metastases observed SEOUL, South Korea , June 2, 2025 /PRNewswire/ -- J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced interim results from the global Phase 1/2 clinical trial of JIN-A02, its fourth-generation EGFR-TKI drug candidate, at the American Society of Clinical Oncology 2025 (ASCO 2025), the world's largest oncology conference, held in Chicago, USA. JIN-A02 is an oral, fourth-generation EGFR-TKI designed to overcome resistance mutations (such as C797S) that develop after treatment failure with third-generation EGFR-TKIs, which are currently the first-line therapy for EGFR-mutant Non-small cell lung cancer (NSCLC). It is currently undergoing clinical trials in South Korea, the United States, Thailand, and other countries. Key efficacy and safety results from Part A (dose escalation) of the multi-center clinical trial (NCT05394831) were presented. 'Confirmed' clinical response observed in patients with disease progression after 3 rd Generation EGFR TKI and chemotherapy One of the key findings of the ASCO presentation was that tumor responses were sustained in specific dose cohorts, with confirmed partial responses (PRs) verified by independent evaluation. Confirmed PRs were observed in 50mg,100mg and 300mg QD dose groups, providing clinical evidence of anti-tumor activity. In the 50 mg dose group, patients achieved a 77.3% reduction in tumor size, maintaining a PR over six consecutive treatment cycles (from cycle 3 to cycle 13). In the 300 mg dose group, a confirmed PR was observed with a 39.7% tumor size reduction, including a significant reduction in brain metastatic lesions. In the 100 mg dose group, a PR was also reported with a 35.3% reduction in tumor size, and brain metastatic lesions remained stable, further supporting the potential of JIN-A02 in treating brain metastases. Safety confirmed up to 300 mg, with therapeutic signals in brain metastases No dose-limiting toxicities (DLTs) or serious adverse events were observed with JIN-A02 at doses up to 300mg, which is six times the dose level when PR was first observed, demonstrating a favorable safety profile even at higher dose levels. The majority of adverse events reported at 300mg were mild (Grade 1-2) and included for the first time, Grade 1 skin rash, diarrhea, and skin desquamation in 3 out of 5 subjects – events commonly associated with EGFR inhibitors and generally considered clinically manageable. Importantly, there were no reports of systemic toxicities such as cardiovascular events or hepatotoxicity, supporting the drug's excellent safety profile. This safety and tolerability have translated into extended treatment durations in real-world settings, with a patient still on JIN-A02 after one year and seven months. In addition, the trial demonstrated notable responses in brain metastases first noted at 100mg, suggesting that JIN-A02 achieves therapeutically relevant concentrations in brain tissue. JIN-A02 gains national spotlight as government grants accelerate development In addition to the ASCO announcement, J INTS BIO continues to achieve noteworthy results in Korea. Recently, it was selected for the '2025 Baby Unicorn Fostering Project' by the Ministry of SMEs and Startups, officially recognizing both our scientific technology and commercialization potential. The 'Baby Unicorn Fostering Project' is a government project that focuses on developing promising startups with innovative technologies and growth potential in the global market as 'potential unicorns'. Companies selected for this project will receive full government support in recognition of their technological prowess and growth potential. With these accolades, JIN-A02 will receive dual funding for its Phase 2 trial and global expansion over the next two years, which is expected to be a decisive point to significantly accelerate the pace of clinical and commercialization in parallel with private investment. It is also significant as a case of securing confidence in the 3 arena of technology, marketability, and global scalability, as the recognition came from different government departments. Based on these achievements, we plan to initiate the Phase 2 clinical trial of JIN-A02 in before the end of this year, in discussions with the US FDA. "The ASCO presentation of JIN-A02's ability to induce anti-cancer responses and its ability to respond to central nervous system metastatic lesions is of great significance," said Dr. Anna Jo, CEO. "The government's continued support is a recognition of our technical capabilities and potential for growth. We will take advantage of this opportunity to accelerate global clinical expansion, technology transfer, and indication expansion to realize our goal of early commercialization"
Korea Herald
4 hours ago
- Korea Herald
Solus to supply key EV battery material to CATL's European plants
Korean battery materials producer Solus Advanced Materials announced Monday that it has secured a contract to supply electrolytic copper foil to Chinese electric vehicle battery juggernaut CATL. Under the agreement, Solus will deliver the key battery component from its Hungarian plant to support CATL's rapidly expanding operations across Europe. While Solus did not disclose the duration or volume of the deal, it confirmed that deliveries will begin in 2026. This marks the first time a Korean foil manufacturer has been selected to supply CATL's European operations. Solus attributed its successful bid to its position as the only Korean electrolytic foil producer currently operating in Europe as well as its technical expertise in foil manufacturing and rapid delivery capabilities. 'This new collaboration with CATL, a powerhouse in the global battery market, confirms Solus Advanced Materials' global competitiveness,' said Solus CEO Kwak Keun-man. 'Through this partnership, we will accelerate innovation in elecfoil technology and fully support CATL in building a localized supply chain in Europe, ultimately enhancing customer satisfaction.' CATL, the world's largest battery maker, currently runs a 14 gigawatt-hour plant in Erfurt, Germany, and is set to open a 100 GWh facility in Hungary later this year. A third plant, co-developed with European automaker Stellantis, is planned for Spain with an expected opening in 2026 — part of CATL's broader strategy to solidify its foothold in the European market amid growing policy headwinds in the US. Solus added that both companies are also exploring joint development of next-generation products. The market responded positively to the announcement. Shares of Solus surged at the opening of Korea's main bourse, Kospi, reaching as high as 10,990 won ($14.51), a 28 percent increase from the previous day's close. As of 12:53 p.m., the stock was trading at 9,790 won, up 14.1 percent from the previous day.
